Stocks / NASDAQ / NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc.

Industry: Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol: NTHI – NASDAQ

Animal Usage: Animal Testing

Our Opinion

NeOnc Technologies Holdings, Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company confirms in corporate disclosures that it utilizes animal subjects for product testing.

“We believe this means we should be able to speed up how quickly we find effective treatments, personalize therapies for patients using their own cells, cut down on animal testing, and potentially expand into diseases beyond brain cancer, such as Alzheimer’s and Parkinson’s.” Read the article for more details

Company Description

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is headquartered in Calabasas, California.

Company Website: https://www.neonc.com

Contact: info@neonc.com